Although the identification of certain molecular markers in cancer cells undergoing EMT remains unclear, the prominent acknowledgment is that the substitution of E-cadherin (E-cad) with N-cadherin (N-cad) is a fundamental molecular hallmark of this process [26, 27]. The gene discussed is CDH1; the disease is cancer.